Trial Profile
A Phase 1/2a Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell or T-Cell Non-Hodgkin Lymphoma (NHL)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Cerdulatinib (Primary) ; Rituximab
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Sezary syndrome; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease
- 14 Dec 2021 Final Results from the PTCL cohort (n=65) assessing efficacy and safety of cerdulatinib monotherapy, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 14 Dec 2021 Results (n=42) assessing the efficacy and safety data are presented for pts in the two FL cohorts, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
- 13 Dec 2021 Status changed from active, no longer recruiting to completed.